DBV Technologies (NASDAQ:DBVT) Issues Quarterly Earnings Results

Key Points

• DBV Technologies reported a quarterly loss of ($1.55) EPS, significantly missing analysts' estimates of ($0.28) by ($1.27).
• The company has a negative net margin of 3,249.99% and a return on equity of -278.24% as it continues its research and development of immunotherapy products.
• Analysts have mixed ratings on DBV Technologies, with two selling, three buying, and one strong buy recommendation, resulting in a consensus rating of "Moderate Buy" with an average target price of $14.75.

DBV Technologies (NASDAQ:DBVT - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.34), Zacks reports. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. The company had revenue of $1.74 million for the quarter, compared to the consensus estimate of $0.64 million.

DBV Technologies Stock Performance

Shares of NASDAQ:DBVT traded up $0.49 during trading hours on Friday, hitting $9.00. The stock had a trading volume of 24,525 shares, compared to its average volume of 26,058. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The firm has a market capitalization of $246.51 million, a price-to-earnings ratio of -1.89 and a beta of -0.58. The stock's fifty day simple moving average is $9.50 and its 200 day simple moving average is $7.41.

Wall Street Analyst Weigh In

DBVT has been the topic of a number of recent research reports. Lifesci Capital raised shares of DBV Technologies to a "strong-buy" rating in a report on Thursday, June 26th. HC Wainwright raised their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the stock a "buy" rating in a report on Monday, May 5th. JMP Securities reissued a "market outperform" rating and issued a $21.00 target price on shares of DBV Technologies in a report on Thursday, June 26th. Citigroup restated an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. Finally, The Goldman Sachs Group upgraded shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a research note on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $14.75.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.